ID   ZR-75-1 GDC-0941-resistant
AC   CVCL_A1FN
DR   cancercelllines; CVCL_A1FN
DR   Cosmic; 2787557
DR   Wikidata; Q102115154
RX   PubMed=26759240;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; GDC-0941).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Tyr (c.3199G>T); Zygosity=Heterozygous; Note=Responsible for pictrelisib resistance (PubMed=26759240).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 30-01-24; Version: 8
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//